Licensing & partnership
Akeso Business Update Invitation
An invitation to an Akeso business-update meeting is accompanied by links to previous announcements; the supplied text does not give meeting logistics. The prior announcements highlight positive ivonescimab trial results, approvals and Chinese reimbursement, as well as cadonilimab approvals and U.S. approval of penpulimab for advanced nasopharyngeal carcinoma. Other links cover new clinical programs and Akeso's ivonescimab licensing collaboration with Summit Therapeutics, valued at up to $5 billion.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.